1 / 22

Grupo evalmed -GRADE ( evalmed.es ) Diciembre 2013

Evaluación GRADE del Estudio SAVOR-TIMI 53: Resultados cardiovasculares de saxagliptina frente a placebo en pacientes con diabetes mellitus tipo 2. Grupo evalmed -GRADE ( evalmed.es ) Diciembre 2013.

hani
Download Presentation

Grupo evalmed -GRADE ( evalmed.es ) Diciembre 2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Evaluación GRADE del Estudio SAVOR-TIMI 53: Resultados cardiovasculares de saxagliptina frente a placebo en pacientes con diabetes mellitus tipo 2. Grupo evalmed-GRADE (evalmed.es) Diciembre 2013

  2. Estudio SAVOR-TIMI 53: Resultados cardiovasculares de saxagliptina frente a placebo en pacientes con diabetes mellitus tipo 2.Scirica BM et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013 Oct 3; 369:1317-1326. INTRODUCCIÓN. A día de hoy no están claras la seguridad cardiovascular y la eficacia de saxagliptina, un inhibidor de la dipeptidilpeptidasa 4 (DPP-4), ni de sus congéneres de subgrupo terapéutico.

  3. C) RESULTADOS.1º Magnitud y precisión de los resultados de las variables:

More Related